{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:10:39Z","timestamp":1787062239626,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T00:00:00Z","timestamp":1691884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T00:00:00Z","timestamp":1691884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This meta-analysis compares the efficacy and safety of Closed-Loop Control (CLC) to Sensor-Augmented Insulin Pump (SAP) for adolescent patients with Type 1 Diabetes Mellitus (T1DM). Eleven randomized-controlled trials were included with a total of 570 patients, from a total of 869 articles found adhering to PRISMA guidelines. The efficacy of the therapies were evaluated from the day, night and during physical activities monitoring of the of the mean blood glucose (BG), Time In Range (TIR), and Standard Deviation (SD) of the glucose variability. The safety measure of the therapies, was assessed from the day and night recording of the hypoglycemic and hyperglycemic events occurred. Pooled results of comparison of mean BG values for day, night and physical activities, \u2212\u00a04.33 [\u2212\u00a06.70, \u2212\u00a01.96] (P\u2009=\u20090.0003), \u2212\u00a016.61 [\u2212\u00a031.68, \u2212\u00a01.54] (P\u2009=\u20090.03) and \u2212\u00a08.27 [\u2212\u00a019.52, 2.99] (P\u2009=\u20090.15). The monitoring for day, night and physical activities for TIR \u2212\u00a013.18 [\u2212\u00a019.18, \u2212\u00a07.17] (P\u2009&lt;\u20090.0001), \u2212\u00a015.36 [\u2212\u00a026.81, \u2212\u00a03.92] (P\u2009=\u20090.009) and \u2212\u00a07.39 [\u2212\u00a017.65, 2.87] (P\u2009=\u20090.16). The day and night results of SD of glucose variability was \u2212\u00a00.40 [\u2212\u00a00.79, \u2212\u00a00.00] (P\u2009=\u20090.05) and \u2212\u00a00.86 [\u2212\u00a02.67, 0.95] (P\u2009=\u20090.35). These values shows the superiority of CLC system in terms of efficacy. The safety evaluation, of the day, night and physical activities observations of average blood glucose goal hypoglycemic events \u2212\u00a00.54 [\u2212\u00a01.86, 0.79] (P\u2009=\u20090.43), 0.04 [\u2212\u00a00.20, 0.27] (P\u2009=\u20090.77) and 0.00 [\u2212\u00a00.25, 0.25] (P\u2009=\u20091.00) and hyperglycemic events \u2212\u00a00.04 [\u2212\u00a00.20, 0.27] (P\u2009=\u20090.77), \u2212\u00a07.11 [\u2212\u00a012.77, \u2212\u00a01.45] (P\u2009=\u20090.01) and \u2212\u00a00.00 [\u2212\u00a00.10, 0.10] (P\u2009=\u20090.97), highlights the commendable safety factor of CLC. The CLC systems can be considered as an ideal preference in the management of adolescents with type 1 diabetes to be used during a 24\u00a0h basis.<\/jats:p>","DOI":"10.1038\/s41598-023-40423-y","type":"journal-article","created":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T06:01:32Z","timestamp":1691906492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of closed-loop control system for type one diabetes in adolescents a meta analysis"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7259-2728","authenticated-orcid":false,"given":"Mosleh","family":"Jabari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,13]]},"reference":[{"issue":"10313","key":"40423_CR1","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(21)02247-9","volume":"398","author":"ZA Bhutta","year":"2021","unstructured":"Bhutta, Z. A. et al. A century past the discovery of insulin: Global progress and challenges for type 1 diabetes among children and adolescents in low-income and middle-income countries. Lancet 398(10313), 1837\u20131850 (2021).","journal-title":"Lancet"},{"issue":"1","key":"40423_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/aam.aam_8_20","volume":"20","author":"S Derrou","year":"2021","unstructured":"Derrou, S. et al. The profile of autoimmunity in type 1 diabetes patients. Ann. Afr. Med. 20(1), 19 (2021).","journal-title":"Ann. Afr. Med."},{"issue":"7","key":"40423_CR3","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14544","volume":"38","author":"G Mebrahtu","year":"2021","unstructured":"Mebrahtu, G., Maniam, J., James, S. & Ogle, G. D. High incidence of type 1 diabetes in adolescents and young adults in Eritrea. Diabet. Med. 38(7), e14544 (2021).","journal-title":"Diabet. Med."},{"issue":"1","key":"40423_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13098-020-00608-1","volume":"13","author":"S Abdoli","year":"2021","unstructured":"Abdoli, S. et al. Cross-national comparison of psychosocial well-being and diabetes outcomes in adults with type 1 diabetes during the COVID-19 pandemic in US, Brazil, and Iran. Diabetol. Metab. Syndr. 13(1), 1\u201312 (2021).","journal-title":"Diabetol. Metab. Syndr."},{"key":"40423_CR5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00296-021-05083-z","volume":"42","author":"M Szab\u0142owski","year":"2022","unstructured":"Szab\u0142owski, M. et al. Coincidence of juvenile idiopathic arthritis and type 1 diabetes: A case-based review. Rheumatol. Int. 42, 371\u2013378 (2022).","journal-title":"Rheumatol. Int."},{"key":"40423_CR6","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/13543784.2022.2022119","volume":"30","author":"C Mignogna","year":"2022","unstructured":"Mignogna, C., Maddaloni, E., D\u2019Onofrio, L. & Buzzetti, R. Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes. Expert Opin. Investig. Drugs 30, 1209\u20131219 (2022).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"40423_CR7","doi-asserted-by":"crossref","unstructured":"Rossi, M. A. & Yosypiv, I. V. Diabetes in children and adolescents. in Diabetes and Kidney Disease, 155\u2013181. (Springer, 2022).","DOI":"10.1007\/978-3-030-86020-2_7"},{"issue":"1","key":"40423_CR8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S2213-8587(21)00245-X","volume":"10","author":"A Ceriello","year":"2022","unstructured":"Ceriello, A. et al. Glycaemic management in diabetes: Old and new approaches. Lancet Diabetes Endocrinol. 10(1), 75\u201384 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"40423_CR9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/archdischild-2015-308336","volume":"101","author":"M G\u00fcemes","year":"2016","unstructured":"G\u00fcemes, M., Rahman, S. A. & Hussain, K. What is a normal blood glucose?. Arch. Dis. Child. 101(6), 569\u2013574 (2016).","journal-title":"Arch. Dis. Child."},{"issue":"10","key":"40423_CR10","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/jdi.13830","volume":"13","author":"T Urakami","year":"2022","unstructured":"Urakami, T. et al. Comparison of the clinical effects of intermittently scanned and real-time continuous glucose monitoring in children and adolescents with type 1 diabetes: A retrospective cohort study. J. Diabetes Investig. 13(10), 1745\u20131752 (2022).","journal-title":"J. Diabetes Investig."},{"key":"40423_CR11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pedn.2022.05.022","volume":"66","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Related factors associated with fear of hypoglycemia in parents of children and adolescents with type 1 diabetes: A systematic review. J. Pediatr. Nurs. 66, 125\u2013135 (2022).","journal-title":"J. Pediatr. Nurs."},{"key":"40423_CR12","volume":"27","author":"BE Marks","year":"2022","unstructured":"Marks, B. E., Williams, K. M., Sherwood, J. S. & Putman, M. S. Practical aspects of diabetes technology use: Continuous glucose monitors, insulin pumps, and automated insulin delivery systems. J. Clin. Transl. Endocrinol. 27, 100282 (2022).","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"40423_CR13","volume-title":"Recent Advances in Insulin Delivery Devices and Modes of Insulin Therapy","author":"I Rai","year":"2021","unstructured":"Rai, I., Wanjari, A. & Acharya, S. Recent Advances in Insulin Delivery Devices and Modes of Insulin Therapy (Springer, 2021)."},{"issue":"6","key":"40423_CR14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.eprac.2021.04.008","volume":"27","author":"G Grunberger","year":"2021","unstructured":"Grunberger, G. et al. American association of clinical endocrinology clinical practice guideline: The use of advanced technology in the management of persons with diabetes mellitus. Endocr. Pract. 27(6), 505\u2013537 (2021).","journal-title":"Endocr. Pract."},{"issue":"3","key":"40423_CR15","doi-asserted-by":"crossref","first-page":"e23475","DOI":"10.2196\/23475","volume":"23","author":"C Eberle","year":"2021","unstructured":"Eberle, C., Stichling, S. & L\u00f6hnert, M. Diabetology 4.0: Scoping review of novel insights and possibilities offered by digitalization. J. Med. Internet Res. 23(3), e23475 (2021).","journal-title":"J. Med. Internet Res."},{"issue":"10","key":"40423_CR16","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.2337\/dc21-0932","volume":"44","author":"J Garcia-Tirado","year":"2021","unstructured":"Garcia-Tirado, J. et al. Advanced closed-loop control system improves postprandial glycemic control compared with a hybrid closed-loop system following unannounced meal. Diabetes Care 44(10), 2379\u20132387 (2021).","journal-title":"Diabetes Care"},{"issue":"1","key":"40423_CR17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2337\/dc20-0257","volume":"44","author":"A Addala","year":"2021","unstructured":"Addala, A. et al. A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: A transatlantic comparison. Diabetes Care 44(1), 133\u2013140 (2021).","journal-title":"Diabetes Care"},{"key":"40423_CR18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/9781119603207.ch9","volume":"1","author":"RJ Kaur","year":"2021","unstructured":"Kaur, R. J., Rizvi, S. R. & Kudva, Y. C. Technology issues: Continuous glucose monitoring, insulin pumps, and closed loop control for patients with diabetes. Clin. Dilemmas Diabetes 1, 115\u2013123 (2021).","journal-title":"Clin. Dilemmas Diabetes"},{"issue":"6","key":"40423_CR19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/dia.2016.0399","volume":"19","author":"LM Huyett","year":"2017","unstructured":"Huyett, L. M. et al. Outpatient closed-loop control with unannounced moderate exercise in adolescents using zone model predictive control. Diabetes Technol. Ther. 19(6), 331\u2013339 (2017).","journal-title":"Diabetes Technol. Ther."},{"issue":"5","key":"40423_CR20","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2337\/dc18-1854","volume":"42","author":"RS Weinstock","year":"2019","unstructured":"Weinstock, R. S. et al. Self-monitoring of blood glucose in youth-onset type 2 diabetes: Results from the TODAY study. Diabetes Care 42(5), 903\u2013909 (2019).","journal-title":"Diabetes Care"},{"issue":"10","key":"40423_CR21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1089\/dia.2021.0089","volume":"23","author":"YC Kudva","year":"2021","unstructured":"Kudva, Y. C. et al. Patient-reported outcomes in a randomized trial of closed-loop control: The pivotal international diabetes closed-loop trial. Diabetes Technol. Ther. 23(10), 673\u2013683 (2021).","journal-title":"Diabetes Technol. Ther."},{"issue":"7","key":"40423_CR22","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2337\/dc15-2344","volume":"39","author":"JE Pinsker","year":"2016","unstructured":"Pinsker, J. E. et al. Randomized crossover comparison of personalized MPC and PID control algorithms for the artificial pancreas. Diabetes Care 39(7), 1135\u20131142 (2016).","journal-title":"Diabetes Care"},{"issue":"7","key":"40423_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-021-01389-1","volume":"21","author":"KA Datye","year":"2021","unstructured":"Datye, K. A., Tilden, D. R., Parmar, A. M., Goethals, E. R. & Jaser, S. S. Advances, challenges, and cost associated with continuous glucose monitor use in adolescents and young adults with type 1 diabetes. Curr. Diabetes Rep. 21(7), 1\u20138 (2021).","journal-title":"Curr. Diabetes Rep."},{"issue":"7","key":"40423_CR24","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2337\/dc15-2468","volume":"39","author":"SM Anderson","year":"2016","unstructured":"Anderson, S. M. et al. Multinational home use of closed-loop control is safe and effective. Diabetes Care 39(7), 1143\u20131150 (2016).","journal-title":"Diabetes Care"},{"issue":"3","key":"40423_CR25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/dia.2014.0259","volume":"17","author":"SA Brown","year":"2015","unstructured":"Brown, S. A. et al. Multinight \u201cbedside\u201d closed-loop control for patients with type 1 diabetes. Diabetes Technol. Ther. 17(3), 203\u2013209 (2015).","journal-title":"Diabetes Technol. Ther."},{"issue":"8","key":"40423_CR26","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.2337\/dc20-0124","volume":"43","author":"SA Brown","year":"2020","unstructured":"Brown, S. A. et al. Glycemic outcomes of use of CLC versus PLGS in type 1 diabetes: a randomized controlled trial. Diabetes Care 43(8), 1822\u20131828 (2020).","journal-title":"Diabetes Care"},{"issue":"7","key":"40423_CR27","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2337\/dc17-2534","volume":"41","author":"ZA Stewart","year":"2018","unstructured":"Stewart, Z. A. et al. Day-and-night closed-loop insulin delivery in a broad population of pregnant women with type 1 diabetes: A randomized controlled crossover trial. Diabetes Care 41(7), 1391\u20131399 (2018).","journal-title":"Diabetes Care"},{"issue":"4","key":"40423_CR28","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2337\/dc20-2250","volume":"44","author":"OJ Collyns","year":"2021","unstructured":"Collyns, O. J. et al. Improved glycemic outcomes with Medtronic MiniMed advanced hybrid closed-loop delivery: Results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care 44(4), 969\u2013975 (2021).","journal-title":"Diabetes Care"},{"key":"40423_CR29","doi-asserted-by":"crossref","first-page":"154953","DOI":"10.1016\/j.metabol.2021.154953","volume":"127","author":"J Ware","year":"2021","unstructured":"Ware, J. & Hovorka, R. Metabolism clinical & experimental: Recent advances in closed-loop insulin delivery. Metabolism 127, 154953 (2021).","journal-title":"Metabolism"},{"issue":"4","key":"40423_CR30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Ann. Internal Med. 151(4), 65 (2009).","journal-title":"Ann. Internal Med."},{"issue":"6","key":"40423_CR31","doi-asserted-by":"crossref","first-page":"e0217655","DOI":"10.1371\/journal.pone.0217655","volume":"14","author":"B Rosner","year":"2019","unstructured":"Rosner, B. & Roman-Urrestarazu, A. Health-related quality of life in paediatric patients with Type 1 diabetes mellitus using insulin infusion systems: A systematic review and meta-analysis. PLoS ONE 14(6), e0217655 (2019).","journal-title":"PLoS ONE"},{"key":"40423_CR32","unstructured":"McKenzie, J. E. et al. Cochrane handbook for systematic reviews of interventions version 62 (updated February 2021). (2021)."},{"issue":"1","key":"40423_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-8-22","volume":"8","author":"A Lundh","year":"2008","unstructured":"Lundh, A. & G\u00f8tzsche, P. C. Recommendations by Cochrane review groups for assessment of the risk of bias in studies. BMC Med. Res. Methodol. 8(1), 1\u20139 (2008).","journal-title":"BMC Med. Res. Methodol."},{"issue":"9","key":"40423_CR34","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1089\/dia.2010.0247","volume":"13","author":"NR Hill","year":"2011","unstructured":"Hill, N. R. et al. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol. Ther. 13(9), 921\u2013928 (2011).","journal-title":"Diabetes Technol. Ther."},{"issue":"1","key":"40423_CR35","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/jep.13159","volume":"26","author":"L Lin","year":"2020","unstructured":"Lin, L. Comparison of four heterogeneity measures for meta-analysis. J. Eval. Clin. Pract. 26(1), 376\u2013384 (2020).","journal-title":"J. Eval. Clin. Pract."},{"key":"40423_CR36","volume-title":"Introduction to Meta-analysis: Dealing with Between-Study Heterogeneity","author":"AA Veroniki","year":"2022","unstructured":"Veroniki, A. A. Introduction to Meta-analysis: Dealing with Between-Study Heterogeneity (Springer, 2022)."},{"issue":"12","key":"40423_CR37","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.2337\/dc17-0883","volume":"40","author":"MD Breton","year":"2017","unstructured":"Breton, M. D. et al. Closed-loop control during intense prolonged outdoor exercise in adolescents with type 1 diabetes: The artificial pancreas ski study. Diabetes Care 40(12), 1644\u20131650 (2017).","journal-title":"Diabetes Care"},{"key":"40423_CR38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1089\/dia.2021.0319","volume":"24","author":"AL Carlson","year":"2021","unstructured":"Carlson, A. L. et al. Safety and glycemic outcomes during the MiniMed\u2122 Advanced Hybrid Closed-Loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol. Ther. 24, 178\u2013189 (2021).","journal-title":"Diabetes Technol. Ther."},{"issue":"6","key":"40423_CR39","first-page":"759","volume":"20","author":"L Ekhlaspour","year":"2019","unstructured":"Ekhlaspour, L. et al. Closed loop control in adolescents and children during winter sports: Use of the tandem control-IQ AP system. Pediatr. Diabetes 20(6), 759\u2013768 (2019).","journal-title":"Pediatr. Diabetes"},{"issue":"5","key":"40423_CR40","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/dia.2020.0572","volume":"23","author":"E Isganaitis","year":"2021","unstructured":"Isganaitis, E. et al. Closed-loop insulin therapy improves glycemic control in adolescents and young adults: Outcomes from the International diabetes closed-loop trial. Diabetes Technol. Ther. 23(5), 342\u2013349 (2021).","journal-title":"Diabetes Technol. Ther."},{"issue":"3","key":"40423_CR41","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2337\/dc19-1310","volume":"43","author":"B Kovatchev","year":"2020","unstructured":"Kovatchev, B. et al. Randomized controlled trial of mobile closed-loop control. Diabetes Care 43(3), 607\u2013615 (2020).","journal-title":"Diabetes Care"},{"issue":"8","key":"40423_CR42","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.2337\/dc16-0817","volume":"39","author":"TT Ly","year":"2016","unstructured":"Ly, T. T. et al. Day-and-night closed-loop control using the unified safety system in adolescents with type 1 diabetes at camp. Diabetes Care 39(8), e106\u2013e107 (2016).","journal-title":"Diabetes Care"},{"issue":"10155","key":"40423_CR43","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(18)31947-0","volume":"392","author":"M Tauschmann","year":"2018","unstructured":"Tauschmann, M. et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: A multicentre, 12-week randomised trial. The Lancet 392(10155), 1321\u20131329 (2018).","journal-title":"The Lancet"},{"issue":"11","key":"40423_CR44","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.2337\/dc16-1094","volume":"39","author":"M Tauschmann","year":"2016","unstructured":"Tauschmann, M. et al. Home use of day-and-night hybrid closed-loop insulin delivery in suboptimally controlled adolescents with type 1 diabetes: A 3-week, free-living, randomized crossover trial. Diabetes Care 39(11), 2019\u20132025 (2016).","journal-title":"Diabetes Care"},{"issue":"7","key":"40423_CR45","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.2337\/dc15-2078","volume":"39","author":"M Tauschmann","year":"2016","unstructured":"Tauschmann, M. et al. Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: A free-living, randomized clinical trial. Diabetes Care 39(7), 1168\u20131174 (2016).","journal-title":"Diabetes Care"},{"issue":"5","key":"40423_CR46","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/dom.12427","volume":"17","author":"H Thabit","year":"2015","unstructured":"Thabit, H. et al. Unsupervised home use of an overnight closed-loop system over 3\u20134 weeks: A pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. Diabetes Obes. Metab. 17(5), 452\u2013458 (2015).","journal-title":"Diabetes Obes. Metab."},{"issue":"22","key":"40423_CR47","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa1509351","volume":"373","author":"H Thabit","year":"2015","unstructured":"Thabit, H. et al. Home use of an artificial beta cell in type 1 diabetes. N. Engl. J. Med. 373(22), 2129\u20132140 (2015).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40423-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40423-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40423-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T07:11:43Z","timestamp":1700464303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40423-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,13]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["40423"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-40423-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,13]]},"assertion":[{"value":"12 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13165"}}